Live Chat
Today's Hours: 8:00am - 8:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Roger N. Rosenberg, editor.
    Summary: Like its preceding editions, this atlas is an indispensable guide to the field of neurology, featuring the most clinically essential images and figures. Chapters offer insight and research written by deeply practiced, knowledgeable neurologists that is supplemented with detailed imagery, tables, algorithms, and delineative drawings. Topics covered include developmental and genetic diseases, neuroendocrine disorders, critical care neurology, cerebrovascular disease, dementias, behavioral neurology, neuro-oncology, movement disorders, epilepsy, neuromuscular diseases, infectious diseases, neuroimmunology, neurotoxic disorders, and headache. The authors also delve into specific issues currently prevalent in neuroscientific research, including Alzheimer's disease, dementia, Machado-Joseph disease, Huntington's disease, and brain scanning with PET and fMRI. The Atlas of Clinical Neurology, 4th Edition serves as a comprehensive and premier visual resource for neurologists.

    Contents:
    Developmental disorders
    Genetic diseases of the nervous system
    Neuroendocrine disorders
    Critical care neurology
    Cerebrovascular disease
    Dementias
    Behavioral neurology
    Neuro-oncology
    Movement disorders
    The epilepsies
    Neuromuscular disease
    Infectious diseases of the nervous system
    Neuroimmunology
    Headache.
    Digital Access Springer 2019
  • Article
    Freeman AI, Al-Bussam N, O'Malley JA, Stutzman L, Bjornsson S, Carter WA.
    J Med Virol. 1977;1(2):79-93.
    Twenty-four patients with cancer and concomitant infections with either herpes virus hominis or varicella zoster virus were treated with polyinosinic-polycytidylic acid (rIn.rCn) to determine: 1) the reliability of rIn.rCn to induce interferon production, and 2) the toxicity of the drug. Seven additional patients with herpes zoster were observed as controls. Two lots of rIn.rCn were used; Lot 1 was consistently effective in stimulating serum interferon at doses of 9 and 12 mg/kg, whereas Lot 2 was effective at doses of 3-12 mg/kg. There was no correlation between rIn.rCn doses within these ranges and the resultant interferon levels. Generally, peak serum interferon occurred within the first day. Toxicity to rIn.rCn consisted of fever in 21/24 patients, mild elevation of liver enzymes in 8/24 patients, and laboratory abnormalities of coagulation in 9 patients. The coagulation abnormalities appeared linearly related to the dose of rIn.rCn used. All these abnormalities were reversible, and none were considered severe of life-threatening. Since rIn.rCn was effective in stimulating interferon and since toxicity was considered acceptable, a randomized double-blind study was initiated to determine whether rIn.rCn is effective in the treatment of herpes zoster.
    Digital Access Access Options